ArticleJournal of the American Society of Nephrology : JASN2020
Urinary Soluble CD163: a Novel Noninvasive Biomarker of Activity for Lupus Nephritis.
Article in Journal of the American Society of Nephrology : JASN, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed, 1 synthesis or guideline pooled it, 105 citations in OpenAlex.
- Biomarkers of Lupus Nephritis Histopathology: Where Do We Stand?Arthritis & rheumatology (Hoboken, N.J.) · 2026Pooled it
- Anifrolumab Treatment Leads to Rapid Reduction in Urinary Biomarkers of Intrarenal Inflammation in Lupus Nephritis: Results From the Phase 2 Randomized Trial.Arthritis & rheumatology (Hoboken, N.J.) · 2026Trial
- Urine proteomic insights from the belimumab in lupus nephritis trial.Lupus science & medicine · 2022Trial
- Mechanism-informed combination therapy and dynamic risk stratification in lupus nephritis: toward durable renal protection.Clinical rheumatology · 2026Review
- CD163: a potential biomarker for lupus nephritis activity.Lupus science & medicine · 2026Article
- Association of Urinary Soluble CD163 With Response to Immunosuppressive Therapy and Renal Relapse in IgAN.Kidney international reports · 2026Article
- Biochemical alterations in inflammation, oxidative stress, and urinary biomarkers associated with renal damage in systemic lupus erythematosus.Journal of medical biochemistry · 2026Article
- Evaluation of clinical, histological and biomarker response after initial therapy of lupus nephritis.Lupus science & medicine · 2026Article
- Serum and urinary soluble CD163 in children with active lupus nephritis.Pediatric rheumatology online journal · 2026Article
- Measurements of urinary biomarkers at 2 years following a lupus nephritis flare are associated with subsequent renal outcomes.Lupus science & medicine · 2026Article
- Urine as a source of biomarkers and biological knowledge in chronic kidney disease.Nature reviews. Nephrology · 2026Review
- Serum uric acid in systemic lupus erythematosus with preserved renal function: a cross-sectional and longitudinal analysis.Frontiers in immunology · 2026Article
- Urine proteins reveal distinct coagulation and complement cascades underlying acute versus chronic lupus nephritis.The Journal of clinical investigation · 2025Article
- Biomarkers in Lupus Nephritis: An Evidence-Based Comprehensive Review.Life (Basel, Switzerland) · 2025Review
- Clinical Predictors of Underlying Histologic Activity in Patients with Lupus Nephritis: A Focus on Urinary Soluble CD163.Journal of clinical medicine · 2025Article
- Innate immune cells in acute and chronic kidney disease.Nature reviews. Nephrology · 2025Review
- CD163 detection in immune check-point inhibitors-related acute interstitial nephritis.Clinical kidney journal · 2025Article
- To biopsy or not to biopsy a teenager with typical idiopathic nephrotic syndrome? Start steroids first.Pediatric nephrology (Berlin, Germany) · 2025Review
- Scavenger receptors: key players in the immunological puzzle of lupus.Frontiers in lupus · 2025Article
- Urinary Immune Complexes Reflect Renal Pathology in Lupus Nephritis.Diagnostics (Basel, Switzerland) · 2024Article
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
Abstract
backgroundClinical distinction between patients with lupus nephritis who have active inflammation or chronic kidney damage is challenging. Studies have shown soluble CD163, which derives from cleavage of the CD163 M2c macrophage receptor and can be quantified in urine, correlates with active lupus nephritis.
methodsWe measured urine CD163 at lupus nephritis flares in patients from a Mexican cohort and cross-sectional and longitudinal United States cohorts. We also performed serial urine CD163 measurements during the treatment of flares in a subset of patients from the Mexican and longitudinal United States cohorts, and assessed response to therapy at 12 months. In addition, we evaluated urinary CD163 agreement with histologic activity in 19 patients from the Mexican cohort who had repeated kidney biopsies on follow-up.
resultsUrinary CD163 levels were significantly higher in patients with active lupus nephritis than in patients with active extrarenal SLE, inactive SLE, and other glomerular diseases, and correlated with disease clinical severity, histologic class, and the histologic activity index. Urinary CD163 increased from 6 months preflare to flare, diminishing progressively in complete and partial responders, whereas it remained elevated in nonresponders. Urinary CD163 <370 ng/mmol at 6 months predicted complete renal response at 12 months with >87% sensitivity and >87% specificity. Urinary CD163 <370 ng/mmol or >370 ng/mmol perfectly agreed (
conclusionsUrinary CD163 reflects histologic inflammation in lupus nephritis and is a promising activity biomarker that varies over time with lupus nephritis activity and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.